関連する実験動画
Updated: Feb 19, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
95.9K
2型糖尿病患者の喫煙に対するグルカゴン類ペプチド-1受容体アゴニストの効果:ランダム化,並行制御の臨床試験の試験プロトコル
Da Chen1, Ziyi Li1, Chenxia Zhou1
1Department of Endocrinology, East Hospital, Tongji University School of Medicine, Shanghai, China.
Frontiers in clinical diabetes and healthcare
|February 18, 2026
まとめ
グルカゴンのようなペプチド-1受容体アゴニスト (GLP-1RAs) は,2型糖尿病患者のニコチン依存を軽減する可能性があります. この試験では,喫煙と脳活動に対するGLP-1RAの効果を調査し,継続的なリクルートを行っています.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 神経科学は神経科学である.
- 依存症医学 薬物中毒医学
背景:
- グルカゴンのようなペプチド-1受容体アゴニスト (GLP-1RAs) は,2型糖尿病 (T2DM) の治療法として確立されています.
- GLP-1RAは報酬経路を調節し,ニコチン依存症の管理における潜在的な役割を示唆する可能性がある.
- T2DM患者における喫煙に対するGLP-1RAの影響に関するランダム化比較試験の証拠は限られている.
研究 の 目的:
- T2DM患者におけるニコチン依存を軽減するGLP-1RAの有効性を評価する.
- GLP-1RAsが喫煙暴露と禁煙率に与える影響を評価する.
- 機能的磁気共鳴画像 (fMRI) を使用して喫煙行動に対する潜在的なGLP-1RA効果の基礎となる神経機構を探求する.
主な方法:
- T2DMとニコチン依存症の46人の男性成人を登録した単一センター,並列グループランダム化制御試験 (ニコチン依存症のFagerströmテスト [FTND]スコア ≥4).
- 参加者は24週間にわたってGLP-1RAまたはディペプチジルペプチダゼ-4阻害剤 (DPP-4i) のいずれかを投与するためにランダムに割り当てられました.
- 主なアウトカムはFTNDスコアの変化であり,二次的なアウトカムには,呼気中の一酸化炭素レベルと禁煙率が含まれています. 実験的なfMRI対策も評価された.
主要な成果:
- 試験が進行中であるため,このセクションはまだ利用できません.
結論:
- 試験が進行中であるため,このセクションはまだ利用できません.
キーワード:
GLP-1RAs (GLP-1RAs) についてT2DMはT2DMで,T2DMはT2DMで,T2DMはタバコの禁煙 禁煙 禁煙 禁煙fMRIは,fMRIで,fMRIは,fMRIで,fMRIは,fMRIで,機能性磁気共鳴画像処理についてグルカゴンのようなペプチド-1受容体アゴニストである.ニコチン依存症 ニコチン依存症2型糖尿病 メリートゥスさらに関連する動画
関連する概念動画
Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
698
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
698
Dipeptidyl Peptidase 4 Inhibitors
734
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
734
Oral Hypoglycemic Agents: Glinides
707
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
707
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
615
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
615
Drugs Acting on Autonomic Ganglia: Stimulants
2.1K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.1K

